Virtual MDR Conformity Assessments

by | Jun 19, 2020 | Audits, FDA, Medical Devices, Requirements, Virtual

When COVID-19 caused the Commission to delay the MDR date of application by a year (May 2021), it was advised that the extra year be spent ensuring compliance with the new regulation. As the pandemic continues to pose an obstacle for the medical device industry, many device manufacturers are also citing the fact that they cannot complete conformity assessments under MDR since it typically requires an in-person visit from notified bodies.

The Commission’s Medical Device Coordination Group (MDCG) recognized the obstacle of in-person audits during the pandemic when it published guidance in April regarding remote assessments.1 The guidance, however, was framed for the soon-to-be-obsolete MDD and IVDD directives and offered very little guidance for MDR provisions. The guidance from the commission did not call out any flexibility as far as the MDR or IVDR, which could leave medical device firms in limbo.

If manufacturers cannot get audited under MDR and IVDR, it could cause bottlenecks as we get closer to the deadline. If firms have to wait until travel restrictions or social distancing measures are lifted before getting audited, that will cause a surge in demand that might potentially overwhelm the system. In light of this potential issue, the MDCG is asking the commission to allow notified bodies to perform virtual audits under MDR and IVDR. Additionally, they called out the concern that unless virtual audits are permitted, devices that are necessary for the pandemic would not be available on time under the new regulations.2

The MDCG references the belief that sufficient technology exists to effectively perform both initial audits under MDR and IVDR and surveillance audits. With teleconferencing technology, and even more innovative products like smart glasses or virtual reality, the group strongly asserts that virtual audits can be just as effective as in-person. If you need help navigating the EU requirements during the pandemic or need guidance on how to conform to MDR and IVDR requirements, EMMA International can help. Give us a call at 248-987-4497 or email info@emmainternational.com to get connected with our team of experts.


1European Commission (April 2020) Guidance on temporary extraordinary measures related to medical device Notified Body audits during COVID-19 quarantine orders and travel restrictions retrieved on 06/18/2020 from: https://ec.europa.eu/docsroom/documents/40705

2MDCG (June 2020) The need for virtual audits under the MDR and IVDR in the context of a pandemic retrieved on 06/18/2020 from: https://www.medtecheurope.org/wp-content/uploads/2020/06/MedTechEurope_PositionPaper_Virtual-MDR_IVDR-Audits_during_pandemic.pdf

Madison Wheeler

Madison Wheeler

Director of Technical Operations - Ms. Wheeler serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Ms. Wheeler also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Ms. Wheeler holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This